Morgan Stanley Reiterates Equal-Weight on Pfizer, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an Equal-Weight rating on Pfizer (NYSE:PFE) and maintained a $43 price target.
July 11, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Pfizer and maintained a $43 price target.
The news is directly about Pfizer and its rating by Morgan Stanley. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's view on the stock has not changed. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100